ReviewFrontiers in surgery2026
Laryngeal transplantation: from experimental feasibility to multidisciplinary clinical reality.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laryngeal transplantation represents one of the most complex forms of vascularized composite allotransplantation (VCA), aiming to restore respiration, phonation, and swallowing in patients with irreversible laryngeal dysfunction. Over the past decades, systematic preclinical research-including refinement of large-animal and rodent models, organ preservation optimization, and elucidation of immunological mechanisms-has laid the scientific foundation for clinical translation. Advances in static cold storage, emerging machine perfusion technologies, and biomarker-based precision monitoring have further improved graft viability and rejection surveillance. Clinically, since the first successful human laryngeal transplantation in 1998, approximately 16 cases worldwide have demonstrated the feasibility of long-term graft survival and meaningful functional recovery. More recently, indications have expanded from trauma-related defects to carefully selected oncologic patients under rigorous immunological and ethical oversight. Surgical progress has focused on microvascular reconstruction, selective neural reinnervation, and airway stabilization, while postoperative management emphasizes individualized immunosuppression, structured rehabilitation, infection prophylaxis, and lifelong surveillance for rejection and malignancy. Nonetheless, major challenges persist, including chronic rejection, variability in functional outcomes, oncologic safety under immunosuppression, donor scarcity, and unresolved ethical issues in a non-life-saving transplant context. Future directions center on integrating multi-omics biomarkers, machine-learning-based monitoring, bioengineered scaffolds, and personalized immunomodulation to enhance long-term graft function and safety. Overall, laryngeal transplantation has evolved from experimental feasibility to a clinically realistic reconstructive strategy, yet its broader application will depend on multidisciplinary innovation and rigorous ethical governance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.